These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29043987)

  • 41. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.
    Tendas A; Lissia MF; Piccioni D; Tirimbelli L; Scaramucci L; Giovannini M; Dentamaro T; Perrotti A; de Fabritiis P; Niscola P
    Support Care Cancer; 2015 Feb; 23(2):303-5. PubMed ID: 25370894
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug therapy for myelodysplastic syndrome: building evidence for action.
    Tefferi A; Letendre L
    Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
    [No Abstract]   [Full Text] [Related]  

  • 43. Decitabine in myelodysplastic syndromes: viewpoints.
    Garcia-Manero G; Saba HI
    Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
    [No Abstract]   [Full Text] [Related]  

  • 44. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
    Shao XR; Liang H; Guan XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
    [No Abstract]   [Full Text] [Related]  

  • 45. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
    Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N
    Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576
    [No Abstract]   [Full Text] [Related]  

  • 46. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 47. 5-Azacytidine for the treatment of myelodysplastic syndromes.
    Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
    Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
    Ogata K; Sei K; Kawahara N; Yamamoto Y
    Br J Haematol; 2020 May; 189(4):e144-e147. PubMed ID: 32130725
    [No Abstract]   [Full Text] [Related]  

  • 51. Intravenous azacitidine for MDS.
    Gore SD
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
    [No Abstract]   [Full Text] [Related]  

  • 52. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 53. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 54. 5-Azacytidine/Azacitidine.
    Müller A; Florek M
    Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report.
    Tsutsumi Y; Ohigashi H; Ito S; Shiratori S; Teshima T
    J Med Case Rep; 2016 Feb; 10():27. PubMed ID: 26838941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

  • 58. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 59. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.
    Voso MT; Fabiani E; Piciocchi A; Matteucci C; Brandimarte L; Finelli C; Pogliani E; Angelucci E; Fioritoni G; Musto P; Greco M; Criscuolo M; Fianchi L; Vignetti M; Santini V; Hohaus S; Mecucci C; Leone G
    Leukemia; 2011 Dec; 25(12):1910-3. PubMed ID: 21760590
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.